Down Field Spectroscopy at Ultrahigh Fields

超高场下场光谱

• 批准号: 10490830
• 负责人: Walter R.T. Witschey
• 金额: $ 20万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-20 至 2026-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10490830
• 关键词: 3-Dimensional; Address; Adenine; Adenosine; Adenosine Triphosphate; Affect; Age; Aging; Amides; Amines; Attenuated; Biological Assay; Biological Markers; Brain; Carnosine; Chemical Shift Imaging; Chemicals; Collaborations; Data; Detection; Development; Diagnosis; Disease; Doctor of Philosophy; Friedreich Ataxia; Glutamates; Glutamine; Goals; Heart; Homeostasis; Human; Imidazole; Institution; Magnetic Resonance; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetism; Malignant Neoplasms; Mass Spectrum Analysis; Measures; Metabolic; Metabolism; Methodology; Methods; Mitochondrial Diseases; Modeling; Molecular; Muscle; Muscular Dystrophies; Myocardial Infarction; Myocardium; N-acetylaspartate; Nerve Degeneration; Niacinamide; Nicotinamide adenine dinucleotide; Noise; Pathologic; Phase; Phosphocreatine; Physiologic pulse; Property; Protons; Rattus; Recovery; Relaxation; Resolution; Role; Scheme; Services; Signal Transduction; Skeletal Muscle; Spectrum Analysis; Techniques; Technology; Therapy Evaluation; Time; Tissues; Training; Treatment Efficacy; Water; Work; age related; biomedical scientist; commercialization; contaminated water; curve fitting; disease diagnosis; efficacy evaluation; experience; experimental study; healthy volunteer; human subject; improved; in vivo; magnetic field; metabolic imaging; new technology; next generation; novel; novel strategies; precision medicine; synergism; targeted treatment; technology research and development; therapeutic evaluation

TR&D3: Downfield Spectroscopy at Ultrahigh Fields Project PIs: Walter Witschey, Ph.D. and Ravinder Reddy, Ph.D. Abstract This technology research and development component focuses on the development of downfield 1H magnetic resonance spectroscopic (DFS) technologies to measure several important metabolites (NAD+, Glutamine, PCr, Carnosine and ATP) that are not accessible from the conventional upfield spectroscopy (UFS), and serve as biomarkers for different diseases. Specifically, it develops novel technologies including (i) Spectral selective excitation pulses and spatially localized pulse sequences with optimal excitation profiles and capable of ultra- short echo acquisition without water suppression (ii) Strategies to detect and assign the DFS metabolites and measure cross-relaxation (iii) Optimal metabolic cycling schemes capable of providing simultaneous UFS and DFS with short echo acquisition and (iv) a post-processing pipeline integrating receive coil selection, eddy current correction and spectral curve fitting and metabolite quantitation. These technological developments are driven by collaborations and service projects from within PENN and from other institutions distributed across the US and abroad. Successful completion of the goals will lead to technologies that contribute to our improved understanding of aging, neurodegeneration, mitochondrial disease in skeletal muscle and heart and, thereby improving diagnosis of these disorders and guiding the development of targeted therapies and enabling longitudinal evaluation of the efficacy of these therapies. Furthermore, wide dissemination of these technologies, potential commercialization, and training of the next generation of biomedical scientists, will have sustained national impact.

TR&D3：超高场下场光谱 项目 PI：Walter Witschey 博士和拉文德·雷迪博士 抽象的 该技术研发部分重点开发低场1H磁 共振光谱 (DFS) 技术可测量多种重要的代谢物（NAD+、谷氨酰胺、PCr、 肌肽和 ATP）无法通过传统的高场光谱 (UFS) 获得，并且可以作为 不同疾病的生物标志物。具体来说，它开发的新技术包括 (i) 光谱选择性 激励脉冲和空间局部脉冲序列具有最佳的激励曲线，并且能够超 无水抑制的短回波采集 (ii) 检测和分配 DFS 代谢物的策略 测量交叉松弛 (iii) 能够同时提供 UFS 和 具有短回波采集功能的 DFS 和 (iv) 集成接收线圈选择、涡流的后处理流程 校正和光谱曲线拟合以及代谢物定量。这些技术的发展是驱动 通过 PENN 内部和分布在美国各地的其他机构的合作和服务项目 和国外。成功完成这些目标将带来有助于我们改进的技术 了解衰老、神经退行性变、骨骼肌和心脏的线粒体疾病，从而 改善这些疾病的诊断并指导靶向治疗的开发并实现 纵向评估这些疗法的功效。此外，这些技术的广泛传播， 潜在的商业化以及下一代生物医学科学家的培训将持续下去 国家影响。